Journal article
Authors list: Jakob, Thilo; Rauber, Michele Myriam; Perez-Riverol, Amilcar; Spillner, Edzard; Blank, Simon
Publication year: 2020
Journal: Current Allergy and Asthma Reports
Volume number: 20
Issue number: 9
ISSN: 1529-7322
eISSN: 1534-6315
Open access status: Hybrid
DOI Link: https://doi.org/10.1007/s11882-020-00943-3
Publisher: Springer
Abstract:
Purpose of Review In Hymenoptera venom allergy, the research focus has moved from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been described as a major allergen of honeybee venom (HBV) with potentially high relevance for diagnostics and therapy of venom allergy. Here, we review recent studies on Api m 10 characteristics as well as its role in component-resolved diagnostics and potential implications for venom-specific immunotherapy (VIT). Recent Findings Api m 10 is a major allergen of low abundance in HBV. It is an obviously unstable protein of unknown function that exhibits homologs in other insect species. Despite its low abundance in HBV, 35 to 72% of HBV-allergic patients show relevant sensitization to this allergen. Api m 10 is a marker allergen for HBV sensitization, which in many cases can help to identify primary sensitization to HBV and, hence, to discriminate between genuine sensitization and cross-reactivity. Moreover, Api m 10 might support personalized risk stratification in VIT, as dominant sensitization to Api m 10 has been identified as risk factor for treatment failure. This might be of particular importance since Api m 10 is strongly underrepresented in some therapeutic preparations commonly used for VIT. Although the role of Api m 10 in HBV allergy and tolerance induction during VIT is not fully understood, it certainly is a useful tool to unravel primary sensitization and individual sensitization profiles in component-resolved diagnostics (CRD). Moreover, a potential of Api m 10 to contribute to personalized treatment strategies in HBV allergy is emerging.
Citation Styles
Harvard Citation style: Jakob, T., Rauber, M., Perez-Riverol, A., Spillner, E. and Blank, S. (2020) The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy, Current Allergy and Asthma Reports, 20(9), Article 48. https://doi.org/10.1007/s11882-020-00943-3
APA Citation style: Jakob, T., Rauber, M., Perez-Riverol, A., Spillner, E., & Blank, S. (2020). The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy. Current Allergy and Asthma Reports. 20(9), Article 48. https://doi.org/10.1007/s11882-020-00943-3
Keywords
Allergen-specific immunotherapy; API M 10; BEE; Component-resolved allergy diagnostics; Honeybee venom allergy; Icarapin; IGE; IMMUNOTHERAPY; RVES V 5; venom immunotherapy